Approved for use through 9/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond on detection of information unless it displays a valid OMS control number

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Substitute for form 1449APTO

L. Confirmation Number | 5,454

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 4

Confirmation Number	9584		
Application Number	10/805,736		
Filing Date	March 22, 2004		
First Named Inventor	Falotico		
Group Art Unit	1614		
Examiner Name	Weddington, K.		
Attomey Docket Number	CRD5071USNP		

xaminer's Cite		T ²
/K.W./	Beutler, E. "Cladribine (2-chlorodeoxyadenosine)", The Lancet, Vol. 340, p. 952 (October 1992)	
	Brehm, B., et al. "8-Blockers of the Third Generation Inhibit Endothelin-1 Liberation, mRNA production and Proliferation of Human Coronary Smooth Muscle and Endothelial Cells", Journal of Cardiovascular Pharmacology, 36 (Suppl. 1):S401-S-403 (2000)	
MANAGEMENT	Brehm, B., et al. "Chronically Elevated Endothelin-1 Concentrations Modulate the ß- Adrenergic Receptor System In Vitro and In Vivo", Journal of Cardiovascular Pharmacology, 36 (Suppl. 1):S157-159 (2000)	
	Campbell & Campbell, "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture", (Table of Contents), Chapter 2, Volume1, pp. 39-52 (1985)	
	Campbell & Campbell, "Cell Biology of Smooth Muscle in Culture: Implications for Atherogenesis", Inter. Angio, 6 pp. 73 (1987)	
	Carson, D., et al. "DNA Strand Breaks, NAD Metabolism, and Programmed Cell Death", Experimental Cell Research 164 p. 273-281 (1986)	
	Clowes and Schwartz, "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery", Cir. Res. 56: 139-145 (1985)	
\vee	Edelman, E., et al. "Pathobiologic Responses to Stenting", American journal of Cardiology Vol. 91, Issue 7, Suppl. 1 (April 1998) pp. 4E-6E	
/K.W./	Fischman, D., et al. "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease", The New England Journal of Medicine, Volume 331:496-501 (1994)	

Examiner Signature	/Kevin Weddington/	Date Considered	07/28/2009	

*EXAMINER: Initial if reference considered, whether or not obtation is in conformance with MFEP 690. Draw line through clation fring in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique obtation designation number (optional): Applicant is to place a check mark here if English language Translation is stached.

11 Applicant's unique obtation designation number (optional): Applicant is to place a check mark here if English language Translation is stached.

11 This collection of information is required by 97 CFR 11 7 and 19.8. The information required to obtation a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by \$S. U.S. C. 12 and \$S. U.R. 1.1. This collection of electronic to the 2 Provint of the process of the process

Approved for use through 9/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO INFORMATION DISCLOSURE

STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 4

der the Paperwork Reduction Act of 1995, no persons are requin

Confirmation Number	9584
Application Number	10/805,736
Filing Date	March 22, 2004
First Named Inventor	Falotico
Group Art Unit	1614
Examiner Name	Weddington, K.
Attorney Docket Number	CRD5071USNP

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/K.W./	Franklin, S., et al. "Pharmacologic Prevention of Restenosis After Coronary Angioplasty: Review of the Randomized Clinical Trials", Coronary Artery Disease, Vol. 4, No. 3 (March 1993)	
	Lang, R., et al. "Effects of Okadaic Acid and ATPyS on Cell Length and CA ²⁺ . Channel Currents Recorded in single Smooth Muscle Cells of the Guinea-Pig Taenia Caeci*, Br. J. Pharmacol. 104, p. 331-336 (1991)	
	Mak, K., et al. "Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization", Department of Cardiolog, Cleveland Clinical Foundation, Ohio p. 255 (1991)	
	Pompa, J., et al. "Clinical Trials of Restenosis After Coronary Angioplasty", Journal of the American Heart Association (Circulation), 84:1426-1436 (1991)	
	Serruys, P. et al. "Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty. A Multicenter Randomized double-Blind Placebo-Controlled Trial", Circulation of the Journal of the American Heart Association, 88 p. 1588-1601 (1993)	
\bigvee	Serruys, P., et al. "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study", Circulation of the American Heart Association, Volume 93(3) p. 412-422 (1996)	
/K.W./	Serruys, P., et al. "A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease", New England Journal of Medicine, Volume 331:489-495 (1994)	

Examiner Signature	/Kevin Weddington/	Date Considered	07/28/2009	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached. 1 Applicants unique dealton designation internal controlled personal to the pack of creek mark ment in English language manistration is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or real benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of thine you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, D. ON DESS. PERD FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 9/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

der the Paperwork Reduction Act of 1995, no persons are requin

(use as many sheets as necessary) Sheet 3 of 4

Confirmation Number	9584
Application Number	10/805,736
Filing Date	March 22, 2004
First Named Inventor	Falotico
Group Art Unit	1614
Examiner Name	Weddington, K.
Attorney Docket Number	CRD5071USNP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T ²
nitials*	No.1	publisher, city and/or country where published	-
		Seto, S., et al. "Mechanism of Deoxyadenosine and 2-Chlorodeoxyadenosine	
/K.W./	l	Toxicity to Nondividing Human Lymphocytes, J. Clin. Invest. Volume 75 p. 377-383	
/17.44./		(1985)	
		Tanaka, H., et al. "Sustained Activation of Vascular Cells and Leukocytes in the	
		Rabbit Aorta after Balloon Injury", Circulation Vol. 88 p. 1788 (19930	
		Tardif, J-C. et al. "Probucol and Multivitamins in the Prevention of Restenosis After	
		Coronary Angioplasty", New England Journal of Medicine, Volume 337:365-372	
		(1997)	
W		Teirstein, P., et al. "Catheter-Based Radiotherapy to Inhibit Restenosis after	
*		Coronary Stenting", New England Journal of Medicine, Vol. 336, p. 1679 (1997)	
07.141.1		Yokoi, H., et al. "Effectiveness of an Antioxidant in Preventing Restenosis After	
/K.W./		Percutaneous Transluminal Coronary Angioplasty: The Probucol Angioplasty	
		Restenosis Trial*, JACC Vol. 30, No. 4 p. 855-862 (1997)	

Examiner Signature	/Kevin Weddington/	Date Considered 07/28/2009

"EXAMINET. Initial if inference considered, whether or not obtation is in conformance with IMEP 000. Draw line through clatron finor. In conformance and not considered. Include copy of this form with next communication to applicant.

1.Applicant's unique obtation designation number (potional). 2Applicant is to place a check mark here if English language Translation is standed. This collection of information is required by 27 CFR 1.7 and 1.85. The Information required to obtain or retain a benefit by the public which is to file (and by the USPT 0 to process) an application. Confidentially is governed by \$5.1.5.C. 122 and \$5.1.7 CFR 1.1.4. This collection is estimated to take 2 hours to any other confidence of the confidence

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.